echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Over 60 new drugs have been approved for clinical use, and the outbreak of bispecific antibodies is imminent?

    Over 60 new drugs have been approved for clinical use, and the outbreak of bispecific antibodies is imminent?

    • Last Update: 2021-07-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com













    Table 1 Bispecific antibody platform






    Table 2 Approved clinical status of domestic double antibodies

    Data source: Yaozhi data


    From the perspective of research and development progress, there are many products in the early clinical stage.
    Kangfang Bio's AK104 and Kangning Jerry's KN046 are progressing quickly and have entered the third clinical phase
    .


    In terms of the number of research and development, Cinda Bio has 7 bispecific antibodies that have entered the clinic, and BeiGene and Baili Pharmaceutical have also entered the clinical stage of a large number of bi-antibody drugs
    .


    summary


    Multispecific drugs are an important part of innovative drug discovery and the future development trend.
    In addition to double antibodies, polyclonal products also have products in the research stage
    .


    It should be noted that the clinical value of drug development is the core
    .
    On July 2, 2021, the Food and Drug Administration issued the "Clinical Value-Oriented Anti-tumor Drug Clinical R&D Guidelines" for soliciting comments, stating that "the research and development of new drugs should provide patients with better treatment options as the highest goal.
    " The unmet clinical needs are the key
    .


    Multispecific drugs have many advantages in theory, but whether they can be transformed into clinical advantages requires more scientific research to prove
    .


    Reference materials:


    Antibody Therapeutics, 2020, Vol.
    3, No.
    1 18–62.
    doi:10.
    1093/abt/tbaa003.


    Editor in charge: Liuli

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.